Literature DB >> 29701902

Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway.

Ismail Ahmed Ismail1,2, Gamal H El-Sokkary3, Saber H Saber2.   

Abstract

Paclitaxel (taxol) is an important agent against many tumours, including breast cancer. Ample data documents that paclitaxel inhibits breast cancer metastasis while others prove that paclitaxel enhances breast cancer metastasis. The mechanisms by which paclitaxel exerts its action are not well established. This study focuses on the effect of paclitaxel, particularly the low doses on breast cancer metastasis and the mechanisms that regulate it. Current results show that, paclitaxel exerts significant cytotoxicity even at low doses in both MCF-7 and MDA-MB-231 cells. Interestingly, paclitaxel significantly inhibits cell invasion and migration, decreases Snail and increases E-cadherin mRNA expression levels at the indicated low doses. Furthermore, paclitaxel-inhibiting breast cancer metastasis is associated with down-regulation of DJ-1 and ID-1 mRNA expression level with a concurrent increase in KLF17 expression. Under the same experimental conditions, paclitaxel induces KLF17 and concurrently represses ID-1 protein levels. Our results show for the first time that paclitaxel inhibits breast cancer metastasis through regulating DJ-1/KLF17/ID-1 signalling pathway; repressed DJ-1 and ID-1 and enhanced KLF17 expression.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  DJ-1; KLF17; breast cancer metastasis; paclitaxel

Year:  2018        PMID: 29701902     DOI: 10.1111/1440-1681.12960

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

Review 1.  Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression.

Authors:  Wook Jin
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

2.  Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.

Authors:  Fatéméh Dubois; Maureen Keller; Julien Hoflack; Elodie Maille; Martine Antoine; Virginie Westeel; Emmanuel Bergot; Elisabeth Quoix; Armelle Lavolé; Laurence Bigay-Game; Jean-Louis Pujol; Alexandra Langlais; Franck Morin; Gérard Zalcman; Guénaëlle Levallet
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

3.  Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput.

Authors:  Yuqing Jia; Robbert Q Kim; Raymond Kooij; Huib Ovaa; Aysegul Sapmaz; Paul P Geurink
Journal:  J Med Chem       Date:  2022-09-23       Impact factor: 8.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.